INCY Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
1.6B
-7.0%
1.7B
+31.5%
1.3B
-15.5%
1.5B
+10.3%
1.4B
Cost of Revenue
108.7M
+3.6%
105.0M
+0.4%
104.5M
-13.7%
121.2M
+22.4%
99.0M
Gross Profit
1.4B
-7.7%
1.6B
+34.3%
1.2B
-15.7%
1.4B
+9.4%
1.3B
Operating Expenses
2.2B
+147.6%
871.2M
+0.5%
867.0M
-17.4%
1.0B
+27.5%
823.5M
R&D
1.8B
+246.6%
517.0M
+0.2%
515.9M
-15.6%
611.4M
+20.7%
506.6M
SG&A
364.3M
+3.6%
351.7M
+7.2%
328.1M
-16.0%
390.4M
+18.6%
329.1M
Operating Income
-708361000
-201.5%
697.9M
+131.8%
301.1M
-10.3%
335.9M
-24.3%
443.5M
EBITDA
-684186000
-194.5%
724.4M
+108.1%
348.1M
-15.9%
414.0M
-11.5%
467.5M
Net Income
-784803000
-234.0%
585.6M
+93.1%
303.3M
+1.4%
299.3M
-29.4%
424.2M
EPS (Basic)
$-3.86
-232.2%
$2.92
+92.1%
$1.52
+0.0%
$1.52
-30.0%
$2.17
EPS (Diluted)
$-3.86
-237.4%
$2.81
+91.2%
$1.47
+0.7%
$1.46
-30.8%
$2.11
Shares (Diluted)
203.2M
-2.4%
208.2M
+0.7%
206.8M
+1.2%
204.4M
+1.5%
201.4M
Incyte Genomics (INCY) — Financials